NBIX Key Stats
- Neurocrine Biosciences' CEO Presents at Bank of America Merrill Lynch Health Car... May 16
- 5 Biotechnology Stocks to Buy Now Investor Place May 15
- A Look At Neurocrine's VMAT-2 Inhibitor As Phase IIb Data Nears May 10
- NEUROCRINE BIOSCIENCES INC Financials May 10
- Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Heal... May 9
- 5 Biotechnology Stocks to Buy Now Investor Place May 8
- Neurocrine Biosciences Inc. Stock Downgraded (NBIX) May 7
- 1 Winner and 4 Losers from This Week’s Earnings Storm May 4
- Neurocrine Biosciences CEO Discuses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 3
- Neurocrine Biosciences Earnings: Here’s Why Investors are Selling Shares Now May 2
NBIX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Neurocrine Biosciences is up 78.24% over the last year vs S&P 500 Total Return up 29.90%, Abbott Laboratories up 32.54%, and Insmed up 313.4%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for NBIX
Pro Report PDF for NBIX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NBIX Pro Report PDF
Pro Strategies Featuring NBIX
Did Neurocrine Biosciences make it into our Pro Portfolio Strategies?